Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

BACKGROUND: Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease. METHODS: We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Donas, Jesus, Martínez-Urbistondo, Diego, Velázquez Kennedy, Kyra, Villares, Paula, Barquin, Arántzazu, Dominguez, Andrea, Rodriguez-Moreno, Juan Francisco, Caro, Elena, Suarez del Villar, Rafael, Nistal-Villan, Estanislao, Yagüe, Monica, Ortiz, Maria, Barba, Maria, Ruiz-Llorente, Sergio, Quiralte, Miguel, Zanin, Massimiliano, Rodríguez, Cristina, Navarro, Paloma, Berraondo, Pedro, Madurga, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151807/
https://www.ncbi.nlm.nih.gov/pubmed/37143685
http://dx.doi.org/10.3389/fimmu.2023.1156603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151807/
https://www.ncbi.nlm.nih.gov/pubmed/37143685
http://dx.doi.org/10.3389/fimmu.2023.1156603

Ejemplares similares